

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

AstraZeneca vaccine efficacy against B.1.351 (South Africa) variant, ED presentations from Sydney quarantine hotels, reinfection rates

Peer reviewed journals featured:

- A randomised controlled trial of AstraZeneca vaccine against B.1.351 (South Africa) variant [here](#)
- Observational studies on:
 - SARS-CoV-2 reinfection rates in Denmark [here](#) and associated commentary [here](#)
 - Emergency department (ED) presentations from Sydney quarantine hotels during COVID-19 [here](#)
 - SARS-CoV-2 infection and transmission in primary schools in England [here](#)
 - Myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients who died from COVID-19 [here](#)
- Commentary on:
 - Disabled people and COVID-19 [here](#)
 - High COVID-19 death rates in UK prisons [here](#)
 - COVID-19 vaccines and variants [here](#)
- A survey on early public adherence with 'stay at home' advice in the US and Australia [here](#)
- An editorial on domestic violence during the pandemic [here](#)

Letters and correspondence discussed:

- Assessing the effect of COVID-19 on mental health in the general population [here](#)
- Sociodemographic indicators of COVID-19 testing among working-age Australians [here](#)
- Onset of erythema multiforme following the first BNT162b2 (Pfizer) vaccination [here](#)
- Acute onset supraclavicular lymphadenopathy after mRNA vaccine [here](#)
- Correspondence about a previously published article on microvascular disease in diabetes and severe COVID-19 outcomes [here](#) and authors' response [here](#)

Pre-peer review articles featured:

- An estimate of the level of neutralising antibody protective against COVID-19 [here](#)
- Associations of the BNT162b2 (Pfizer) vaccine effectiveness with age and comorbidities [here](#)

Guidance and reports

- The World Health Organization published guidance recommendations for the use of Ad26.COV2.S (Johnson & Johnson) vaccine [here](#) and background document [here](#)
- The Canadian Society of Allergy and Clinical Immunology guidance on COVID-19 vaccine administration in people with allergies or immunocompromise [here](#)
- Australia's Therapeutic Goods Administration (TGA) notes reports of anaphylaxis (severe allergic reaction) to AstraZeneca vaccine [here](#)

News and blogs

- A call for global vaccine equity [here](#)
- Seeing through the fog of post-acute COVID-19 syndrome [here](#)
- Innovators target vaccines for variants and shortages in the global South [here](#)
- The UK's Institute of Economic Affairs used COVID-19 to brief against the NHS [here](#)
- Health experts discuss vaccines, school openings and more [here](#)
- An interview with the former head of the Centers for Disease Control and Protection (CDC), about US efforts to control COVID-19 [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.

The [vaccine page](#) features a one-page 'In the news' summary on the suspension of AstraZeneca vaccine rollout in many countries, and the underlying evidence base.